Featured Articles

1. Accelerating Parkinson's Disease Clinical Research Through CHDR's Monocentre Recruitment Capabilities 1/14/2026

   Centralized PD trials reduce variability, accelerate enrolment, and enable genetic stratification for targeted therapies. This streamlined model delivers high-quality data and faster timelines, helping sponsors move confidently from early-phase research to late-stage development.

2. Navigating The Enrollment Bottleneck In Early Oncology Trials 1/12/2026

   Slow oncology trial enrollment raises costs and delays progress. AI prescreening, patient-focused engagement, and early pharmacology studies help accelerate recruitment and optimize trial design.

3. 6 Key Implications Of EU Clinical Trials Regulation 1/7/2026

   Centralized submissions, greater transparency, and stronger patient protections reshape EU clinical trials, impacting timelines, costs, and strategies for sponsors and CROs.

4. Psychiatric Drug Development Renaissance: With Familiar Risks 1/6/2026

   Emerging psychiatric therapies bring hope, but progress is fragile. Biomarker-driven, mechanism-first approaches help overcome biological, regulatory, and commercial barriers.

5. Trailblazing Clinical Drug Development In Dermatology 1/6/2026

   AI, imaging, and biomarkers are transforming trials, reducing subjectivity and improving sensitivity while enabling decentralized designs, faster timelines, and more precise insights.

6. Year-In-Review: Clinical Research Today And Tomorrow 12/10/2025

   As the industry prepares for 2026, sponsors and investors alike face a pivotal moment — one that demands a more deliberate, insight-driven approach to early clinical development.

7. The Impact Of Expert PK/PD Modeling In Psychedelic Research 12/2/2025

   Model-informed development that integrates preclinical and literature-based data is enabling smarter predictions of exposure and safety, transforming psychedelic research and advancing clinical innovation.

8. The Evolving Role Of Healthy Participants In Early Immuno-Oncology Trials 11/21/2025

   Explore how leveraging healthy participants, advanced immune-challenge models, and high-dimensional biomarker analyses can transform early immuno-oncology development.

9. Bridging The Trust Gap: How Patient Advocacy Groups Transforms Trial Recruitment 10/27/2025

   Explore how collaboration between researchers and Patient Advocacy Groups (PAGs) can bridge the trust gap that undermines recruitment and can make trial participation more approachable and meaningful.

10. The Immunotherapy Revolution's Path To Precision 10/27/2025

    Learn how comprehensive immune profiling and translational models can illuminate these mechanisms, inform dose selection, and guide the next generation of immunotherapies toward safer, more targeted innovation.